compass_positive_tagline-01.png
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 03, 2021 07:00 ET | COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
December 01, 2021 07:00 ET | COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
compass_positive_tagline-01.png
COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 23, 2021 07:00 ET | COMPASS Pathways
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021 07:00 ET | COMPASS Pathways
Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological...
compass_positive_tagline-01.png
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
November 03, 2021 08:00 ET | COMPASS Pathways
London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 20, 2021 09:00 ET | COMPASS Pathways
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...
compass_positive_tagline-01.png
COMPASS Pathways is granted new US patent for crystalline psilocybin
October 19, 2021 07:00 ET | COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
September 14, 2021 07:00 ET | COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an...
compass_positive_tagline-01.png
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET | COMPASS Pathfinder Ltd.
      COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...
compass_positive_tagline-01.png
Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
July 29, 2021 08:30 ET | COMPASS Pathfinder Ltd.
COMPASS announces changes to its Executive Team London, UK – 29 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating...